{"pmid":32027631,"pmcid":"PMC7004396","title":"Initial Public Health Response and Interim Clinical Guidance for the 2019 Novel Coronavirus Outbreak - United States, December 31, 2019-February 4, 2020.","text":["Initial Public Health Response and Interim Clinical Guidance for the 2019 Novel Coronavirus Outbreak - United States, December 31, 2019-February 4, 2020.","On December 31, 2019, Chinese health officials reported a cluster of cases of acute respiratory illness in persons associated with the Hunan seafood and animal market in the city of Wuhan, Hubei Province, in central China. On January 7, 2020, Chinese health officials confirmed that a novel coronavirus (2019-nCoV) was associated with this initial cluster (1). As of February 4, 2020, a total of 20,471 confirmed cases, including 2,788 (13.6%) with severe illness,* and 425 deaths (2.1%) had been reported by the National Health Commission of China (2). Cases have also been reported in 26 locations outside of mainland China, including documentation of some person-to-person transmission and one death (2). As of February 4, 11 cases had been reported in the United States. On January 30, the World Health Organization (WHO) Director-General declared that the 2019-nCoV outbreak constitutes a Public Health Emergency of International Concern.(dagger) On January 31, the U.S. Department of Health and Human Services (HHS) Secretary declared a U.S. public health emergency to respond to 2019-nCoV.( section sign) Also on January 31, the president of the United States signed a \"Proclamation on Suspension of Entry as Immigrants and Nonimmigrants of Persons who Pose a Risk of Transmitting 2019 Novel Coronavirus,\" which limits entry into the United States of persons who traveled to mainland China to U.S. citizens and lawful permanent residents and their families (3). CDC, multiple other federal agencies, state and local health departments, and other partners are implementing aggressive measures to slow transmission of 2019-nCoV in the United States (4,5). These measures require the identification of cases and their contacts in the United States and the appropriate assessment and care of travelers arriving from mainland China to the United States. These measures are being implemented in anticipation of additional 2019-nCoV cases in the United States. Although these measures might not prevent the eventual establishment of ongoing, widespread transmission of the virus in the United States, they are being implemented to 1) slow the spread of illness; 2) provide time to better prepare health care systems and the general public to be ready if widespread transmission with substantial associated illness occurs; and 3) better characterize 2019-nCoV infection to guide public health recommendations and the development of medical countermeasures including diagnostics, therapeutics, and vaccines. Public health authorities are monitoring the situation closely. As more is learned about this novel virus and this outbreak, CDC will rapidly incorporate new knowledge into guidance for action by CDC and state and local health departments.","MMWR Morb Mortal Wkly Rep","Patel, Anita","Jernigan, Daniel B","32027631"],"abstract":["On December 31, 2019, Chinese health officials reported a cluster of cases of acute respiratory illness in persons associated with the Hunan seafood and animal market in the city of Wuhan, Hubei Province, in central China. On January 7, 2020, Chinese health officials confirmed that a novel coronavirus (2019-nCoV) was associated with this initial cluster (1). As of February 4, 2020, a total of 20,471 confirmed cases, including 2,788 (13.6%) with severe illness,* and 425 deaths (2.1%) had been reported by the National Health Commission of China (2). Cases have also been reported in 26 locations outside of mainland China, including documentation of some person-to-person transmission and one death (2). As of February 4, 11 cases had been reported in the United States. On January 30, the World Health Organization (WHO) Director-General declared that the 2019-nCoV outbreak constitutes a Public Health Emergency of International Concern.(dagger) On January 31, the U.S. Department of Health and Human Services (HHS) Secretary declared a U.S. public health emergency to respond to 2019-nCoV.( section sign) Also on January 31, the president of the United States signed a \"Proclamation on Suspension of Entry as Immigrants and Nonimmigrants of Persons who Pose a Risk of Transmitting 2019 Novel Coronavirus,\" which limits entry into the United States of persons who traveled to mainland China to U.S. citizens and lawful permanent residents and their families (3). CDC, multiple other federal agencies, state and local health departments, and other partners are implementing aggressive measures to slow transmission of 2019-nCoV in the United States (4,5). These measures require the identification of cases and their contacts in the United States and the appropriate assessment and care of travelers arriving from mainland China to the United States. These measures are being implemented in anticipation of additional 2019-nCoV cases in the United States. Although these measures might not prevent the eventual establishment of ongoing, widespread transmission of the virus in the United States, they are being implemented to 1) slow the spread of illness; 2) provide time to better prepare health care systems and the general public to be ready if widespread transmission with substantial associated illness occurs; and 3) better characterize 2019-nCoV infection to guide public health recommendations and the development of medical countermeasures including diagnostics, therapeutics, and vaccines. Public health authorities are monitoring the situation closely. As more is learned about this novel virus and this outbreak, CDC will rapidly incorporate new knowledge into guidance for action by CDC and state and local health departments."],"journal":"MMWR Morb Mortal Wkly Rep","authors":["Patel, Anita","Jernigan, Daniel B"],"date":"2020-02-07T11:00:00Z","year":2020,"_id":"32027631","week":"20206|Feb 03 - Feb 09","doi":"10.15585/mmwr.mm6905e1","link_erratum_in":"32053580","source":"PubMed","locations":["United States","Hubei","Wuhan","USA","China","Chinese","Hunan"],"countries":["United States","China"],"countries_codes":["USA|United States","CHN|China"],"topics":["General Info"],"weight":1,"_version_":1661359647142969344,"score":6.7365713,"similar":[{"pmid":32106216,"title":"Update: Public Health Response to the Coronavirus Disease 2019 Outbreak - United States, February 24, 2020.","text":["Update: Public Health Response to the Coronavirus Disease 2019 Outbreak - United States, February 24, 2020.","An outbreak of coronavirus disease 2019 (COVID-19) caused by the 2019 novel coronavirus (SARS-CoV-2) began in Wuhan, Hubei Province, China in December 2019, and has spread throughout China and to 31 other countries and territories, including the United States (1). As of February 23, 2020, there were 76,936 reported cases in mainland China and 1,875 cases in locations outside mainland China (1). There have been 2,462 associated deaths worldwide; no deaths have been reported in the United States. Fourteen cases have been diagnosed in the United States, and an additional 39 cases have occurred among repatriated persons from high-risk settings, for a current total of 53 cases within the United States. This report summarizes the aggressive measures (2,3) that CDC, state and local health departments, multiple other federal agencies, and other partners are implementing to slow and try to contain transmission of COVID-19 in the United States. These measures require the identification of cases and contacts of persons with COVID-19 in the United States and the recommended assessment, monitoring, and care of travelers arriving from areas with substantial COVID-19 transmission. Although these measures might not prevent widespread transmission of the virus in the United States, they are being implemented to 1) slow the spread of illness; 2) provide time to better prepare state and local health departments, health care systems, businesses, educational organizations, and the general public in the event that widespread transmission occurs; and 3) better characterize COVID-19 to guide public health recommendations and the development and deployment of medical countermeasures, including diagnostics, therapeutics, and vaccines. U.S. public health authorities are monitoring the situation closely, and CDC is coordinating efforts with the World Health Organization (WHO) and other global partners. Interim guidance is available at https://www.cdc.gov/coronavirus/index.html. As more is learned about this novel virus and this outbreak, CDC will rapidly incorporate new knowledge into guidance for action by CDC, state and local health departments, health care providers, and communities.","MMWR Morb Mortal Wkly Rep","Jernigan, Daniel B","32106216"],"abstract":["An outbreak of coronavirus disease 2019 (COVID-19) caused by the 2019 novel coronavirus (SARS-CoV-2) began in Wuhan, Hubei Province, China in December 2019, and has spread throughout China and to 31 other countries and territories, including the United States (1). As of February 23, 2020, there were 76,936 reported cases in mainland China and 1,875 cases in locations outside mainland China (1). There have been 2,462 associated deaths worldwide; no deaths have been reported in the United States. Fourteen cases have been diagnosed in the United States, and an additional 39 cases have occurred among repatriated persons from high-risk settings, for a current total of 53 cases within the United States. This report summarizes the aggressive measures (2,3) that CDC, state and local health departments, multiple other federal agencies, and other partners are implementing to slow and try to contain transmission of COVID-19 in the United States. These measures require the identification of cases and contacts of persons with COVID-19 in the United States and the recommended assessment, monitoring, and care of travelers arriving from areas with substantial COVID-19 transmission. Although these measures might not prevent widespread transmission of the virus in the United States, they are being implemented to 1) slow the spread of illness; 2) provide time to better prepare state and local health departments, health care systems, businesses, educational organizations, and the general public in the event that widespread transmission occurs; and 3) better characterize COVID-19 to guide public health recommendations and the development and deployment of medical countermeasures, including diagnostics, therapeutics, and vaccines. U.S. public health authorities are monitoring the situation closely, and CDC is coordinating efforts with the World Health Organization (WHO) and other global partners. Interim guidance is available at https://www.cdc.gov/coronavirus/index.html. As more is learned about this novel virus and this outbreak, CDC will rapidly incorporate new knowledge into guidance for action by CDC, state and local health departments, health care providers, and communities."],"journal":"MMWR Morb Mortal Wkly Rep","authors":["Jernigan, Daniel B"],"date":"2020-02-28T11:00:00Z","year":2020,"_id":"32106216","week":"20209|Feb 24 - Mar 01","doi":"10.15585/mmwr.mm6908e1","source":"PubMed","locations":["United States","Hubei","USA","Wuhan","China"],"countries":["United States","China"],"countries_codes":["USA|United States","CHN|China"],"topics":["General Info"],"weight":1,"_version_":1661359647525699584,"score":293.83362},{"pmid":32053579,"pmcid":"PMC7017962","title":"Persons Evaluated for 2019 Novel Coronavirus - United States, January 2020.","text":["Persons Evaluated for 2019 Novel Coronavirus - United States, January 2020.","In December 2019, a cluster of cases of pneumonia emerged in Wuhan City in central China's Hubei Province. Genetic sequencing of isolates obtained from patients with pneumonia identified a novel coronavirus (2019-nCoV) as the etiology (1). As of February 4, 2020, approximately 20,000 confirmed cases had been identified in China and an additional 159 confirmed cases in 23 other countries, including 11 in the United States (2,3). On January 17, CDC and the U.S. Department of Homeland Security's Customs and Border Protection began health screenings at U.S. airports to identify ill travelers returning from Wuhan City (4). CDC activated its Emergency Operations Center on January 21 and formalized a process for inquiries regarding persons suspected of having 2019-nCoV infection (2). As of January 31, 2020, CDC had responded to clinical inquiries from public health officials and health care providers to assist in evaluating approximately 650 persons thought to be at risk for 2019-nCoV infection. Guided by CDC criteria for the evaluation of persons under investigation (PUIs) (5), 210 symptomatic persons were tested for 2019-nCoV; among these persons, 148 (70%) had travel-related risk only, 42 (20%) had close contact with an ill laboratory-confirmed 2019-nCoV patient or PUI, and 18 (9%) had both travel- and contact-related risks. Eleven of these persons had laboratory-confirmed 2019-nCoV infection. Recognizing persons at risk for 2019-nCoV is critical to identifying cases and preventing further transmission. Health care providers should remain vigilant and adhere to recommended infection prevention and control practices when evaluating patients for possible 2019-nCoV infection (6). Providers should consult with their local and state health departments when assessing not only ill travelers from 2019-nCoV-affected countries but also ill persons who have been in close contact with patients with laboratory-confirmed 2019-nCoV infection in the United States.","MMWR Morb Mortal Wkly Rep","Bajema, Kristina L","Oster, Alexandra M","McGovern, Olivia L","Lindstrom, Stephen","Stenger, Mark R","Anderson, Tara C","Isenhour, Cheryl","Clarke, Kevin R","Evans, Mary E","Chu, Victoria T","Biggs, Holly M","Kirking, Hannah L","Gerber, Susan I","Hall, Aron J","Fry, Alicia M","Oliver, Sara E","32053579"],"abstract":["In December 2019, a cluster of cases of pneumonia emerged in Wuhan City in central China's Hubei Province. Genetic sequencing of isolates obtained from patients with pneumonia identified a novel coronavirus (2019-nCoV) as the etiology (1). As of February 4, 2020, approximately 20,000 confirmed cases had been identified in China and an additional 159 confirmed cases in 23 other countries, including 11 in the United States (2,3). On January 17, CDC and the U.S. Department of Homeland Security's Customs and Border Protection began health screenings at U.S. airports to identify ill travelers returning from Wuhan City (4). CDC activated its Emergency Operations Center on January 21 and formalized a process for inquiries regarding persons suspected of having 2019-nCoV infection (2). As of January 31, 2020, CDC had responded to clinical inquiries from public health officials and health care providers to assist in evaluating approximately 650 persons thought to be at risk for 2019-nCoV infection. Guided by CDC criteria for the evaluation of persons under investigation (PUIs) (5), 210 symptomatic persons were tested for 2019-nCoV; among these persons, 148 (70%) had travel-related risk only, 42 (20%) had close contact with an ill laboratory-confirmed 2019-nCoV patient or PUI, and 18 (9%) had both travel- and contact-related risks. Eleven of these persons had laboratory-confirmed 2019-nCoV infection. Recognizing persons at risk for 2019-nCoV is critical to identifying cases and preventing further transmission. Health care providers should remain vigilant and adhere to recommended infection prevention and control practices when evaluating patients for possible 2019-nCoV infection (6). Providers should consult with their local and state health departments when assessing not only ill travelers from 2019-nCoV-affected countries but also ill persons who have been in close contact with patients with laboratory-confirmed 2019-nCoV infection in the United States."],"journal":"MMWR Morb Mortal Wkly Rep","authors":["Bajema, Kristina L","Oster, Alexandra M","McGovern, Olivia L","Lindstrom, Stephen","Stenger, Mark R","Anderson, Tara C","Isenhour, Cheryl","Clarke, Kevin R","Evans, Mary E","Chu, Victoria T","Biggs, Holly M","Kirking, Hannah L","Gerber, Susan I","Hall, Aron J","Fry, Alicia M","Oliver, Sara E"],"date":"2020-02-14T11:00:00Z","year":2020,"_id":"32053579","week":"20207|Feb 10 - Feb 16","doi":"10.15585/mmwr.mm6906e1","source":"PubMed","locations":["United States","Hubei","USA","Wuhan","China"],"countries":["United States","China"],"countries_codes":["USA|United States","CHN|China"],"topics":["Mechanism"],"weight":1,"_version_":1661359647250972672,"score":274.92545},{"pmid":32141588,"title":"Coronavirus Disease 2019 outbreak: preparedness and readiness of countries in the Eastern Mediterranean Region.","text":["Coronavirus Disease 2019 outbreak: preparedness and readiness of countries in the Eastern Mediterranean Region.","On 31 December 2019, a cluster of acute respiratory illness was reported from China and later confirmed as novel coronavirus on 7 January 2020. This virus is the same member of the coronavirus family that caused the severe acute respiratory syndrome (SARS-CoV) reported in China 2003, and Middle East respiratory syndrome (MERS-CoV) reported in Saudi Arabia in 2012. The initial cases have been linked to a live seafood market in Wuhan, China, and the specific animal source is yet to be determined. The detection of this new virus in humans without knowing the source of the infection has raised greatly heightened concerns not only in China, but also internationally. To date, the outbreak has spread to most provinces in China and 25 other countries within a relatively short period. Consequent to its spread, Dr Tedros Ghebreyesus, Director General of the World Health Organization (WHO), declared the outbreak a Public Health Emergency of International Concern (PHEIC) on 30 January 2020.","East Mediterr Health J","Al-Mandhari, Ahmed","Samhouri, Dalia","Abubakar, Abdinasir","Brennan, Richard","32141588"],"abstract":["On 31 December 2019, a cluster of acute respiratory illness was reported from China and later confirmed as novel coronavirus on 7 January 2020. This virus is the same member of the coronavirus family that caused the severe acute respiratory syndrome (SARS-CoV) reported in China 2003, and Middle East respiratory syndrome (MERS-CoV) reported in Saudi Arabia in 2012. The initial cases have been linked to a live seafood market in Wuhan, China, and the specific animal source is yet to be determined. The detection of this new virus in humans without knowing the source of the infection has raised greatly heightened concerns not only in China, but also internationally. To date, the outbreak has spread to most provinces in China and 25 other countries within a relatively short period. Consequent to its spread, Dr Tedros Ghebreyesus, Director General of the World Health Organization (WHO), declared the outbreak a Public Health Emergency of International Concern (PHEIC) on 30 January 2020."],"journal":"East Mediterr Health J","authors":["Al-Mandhari, Ahmed","Samhouri, Dalia","Abubakar, Abdinasir","Brennan, Richard"],"date":"2020-03-07T11:00:00Z","year":2020,"_id":"32141588","week":"202010|Mar 02 - Mar 08","doi":"10.26719/2020.26.2.136","source":"PubMed","locations":["Saudi Arabia","Wuhan","China"],"countries":["China","Saudi Arabia"],"countries_codes":["CHN|China","SAU|Saudi Arabia"],"topics":["General Info"],"weight":1,"_version_":1661359647734366209,"score":240.55669},{"pmid":32134909,"title":"Active Monitoring of Persons Exposed to Patients with Confirmed COVID-19 - United States, January-February 2020.","text":["Active Monitoring of Persons Exposed to Patients with Confirmed COVID-19 - United States, January-February 2020.","In December 2019, an outbreak of coronavirus disease 2019 (COVID-19), caused by the virus SARS-CoV-2, began in Wuhan, China (1). The disease spread widely in China, and, as of February 26, 2020, COVID-19 cases had been identified in 36 other countries and territories, including the United States. Person-to-person transmission has been widely documented, and a limited number of countries have reported sustained person-to-person spread.* On January 20, state and local health departments in the United States, in collaboration with teams deployed from CDC, began identifying and monitoring all persons considered to have had close contact(dagger) with patients with confirmed COVID-19 (2). The aims of these efforts were to ensure rapid evaluation and care of patients, limit further transmission, and better understand risk factors for transmission.","MMWR Morb Mortal Wkly Rep","Burke, Rachel M","Midgley, Claire M","Dratch, Alissa","Fenstersheib, Marty","Haupt, Thomas","Holshue, Michelle","Ghinai, Isaac","Jarashow, M Claire","Lo, Jennifer","McPherson, Tristan D","Rudman, Sara","Scott, Sarah","Hall, Aron J","Fry, Alicia M","Rolfes, Melissa A","32134909"],"abstract":["In December 2019, an outbreak of coronavirus disease 2019 (COVID-19), caused by the virus SARS-CoV-2, began in Wuhan, China (1). The disease spread widely in China, and, as of February 26, 2020, COVID-19 cases had been identified in 36 other countries and territories, including the United States. Person-to-person transmission has been widely documented, and a limited number of countries have reported sustained person-to-person spread.* On January 20, state and local health departments in the United States, in collaboration with teams deployed from CDC, began identifying and monitoring all persons considered to have had close contact(dagger) with patients with confirmed COVID-19 (2). The aims of these efforts were to ensure rapid evaluation and care of patients, limit further transmission, and better understand risk factors for transmission."],"journal":"MMWR Morb Mortal Wkly Rep","authors":["Burke, Rachel M","Midgley, Claire M","Dratch, Alissa","Fenstersheib, Marty","Haupt, Thomas","Holshue, Michelle","Ghinai, Isaac","Jarashow, M Claire","Lo, Jennifer","McPherson, Tristan D","Rudman, Sara","Scott, Sarah","Hall, Aron J","Fry, Alicia M","Rolfes, Melissa A"],"date":"2020-03-06T11:00:00Z","year":2020,"_id":"32134909","week":"202010|Mar 02 - Mar 08","doi":"10.15585/mmwr.mm6909e1","source":"PubMed","locations":["- United States","United States","Wuhan","China"],"countries":["United States","China"],"countries_codes":["USA|United States","CHN|China"],"topics":["General Info"],"weight":1,"_version_":1661359647697666048,"score":228.06815},{"pmid":32088679,"title":"2019-nCoV (Wuhan virus), a novel Coronavirus: human-to-human transmission, travel-related cases, and vaccine readiness.","text":["2019-nCoV (Wuhan virus), a novel Coronavirus: human-to-human transmission, travel-related cases, and vaccine readiness.","On 31 December 2019 the Wuhan Health Commission reported a cluster of atypical pneumonia cases that was linked to a wet market in the city of Wuhan, China. The first patients began experiencing symptoms of illness in mid-December 2019. Clinical isolates were found to contain a novel coronavirus with similarity to bat coronaviruses. As of 28 January 2020, there are in excess of 4,500 laboratory-confirmed cases, with > 100 known deaths. As with the SARS-CoV, infections in children appear to be rare. Travel-related cases have been confirmed in multiple countries and regions outside mainland China including Germany, France, Thailand, Japan, South Korea, Vietnam, Canada, and the United States, as well as Hong Kong and Taiwan. Domestically in China, the virus has also been noted in several cities and provinces with cases in all but one provinence. While zoonotic transmission appears to be the original source of infections, the most alarming development is that human-to-human transmission is now prevelant. Of particular concern is that many healthcare workers have been infected in the current epidemic. There are several critical clinical questions that need to be resolved, including how efficient is human-to-human transmission? What is the animal reservoir? Is there an intermediate animal reservoir? Do the vaccines generated to the SARS-CoV or MERS-CoV or their proteins offer protection against 2019-nCoV? We offer a research perspective on the next steps for the generation of vaccines. We also present data on the use of in silico docking in gaining insight into 2019-nCoV Spike-receptor binding to aid in therapeutic development. Diagnostic PCR protocols can be found at https://www.who.int/health-topics/coronavirus/laboratory-diagnostics-for-novel-co ronavirus.","J Infect Dev Ctries","Ralph, Robyn","Lew, Jocelyne","Zeng, Tiansheng","Francis, Magie","Xue, Bei","Roux, Melissa","Toloue Ostadgavahi, Ali","Rubino, Salvatore","Dawe, Nicholas J","Al-Ahdal, Mohammed N","Kelvin, David J","Richardson, Christopher D","Kindrachuk, Jason","Falzarano, Darryl","Kelvin, Alyson Anne","32088679"],"abstract":["On 31 December 2019 the Wuhan Health Commission reported a cluster of atypical pneumonia cases that was linked to a wet market in the city of Wuhan, China. The first patients began experiencing symptoms of illness in mid-December 2019. Clinical isolates were found to contain a novel coronavirus with similarity to bat coronaviruses. As of 28 January 2020, there are in excess of 4,500 laboratory-confirmed cases, with > 100 known deaths. As with the SARS-CoV, infections in children appear to be rare. Travel-related cases have been confirmed in multiple countries and regions outside mainland China including Germany, France, Thailand, Japan, South Korea, Vietnam, Canada, and the United States, as well as Hong Kong and Taiwan. Domestically in China, the virus has also been noted in several cities and provinces with cases in all but one provinence. While zoonotic transmission appears to be the original source of infections, the most alarming development is that human-to-human transmission is now prevelant. Of particular concern is that many healthcare workers have been infected in the current epidemic. There are several critical clinical questions that need to be resolved, including how efficient is human-to-human transmission? What is the animal reservoir? Is there an intermediate animal reservoir? Do the vaccines generated to the SARS-CoV or MERS-CoV or their proteins offer protection against 2019-nCoV? We offer a research perspective on the next steps for the generation of vaccines. We also present data on the use of in silico docking in gaining insight into 2019-nCoV Spike-receptor binding to aid in therapeutic development. Diagnostic PCR protocols can be found at https://www.who.int/health-topics/coronavirus/laboratory-diagnostics-for-novel-co ronavirus."],"journal":"J Infect Dev Ctries","authors":["Ralph, Robyn","Lew, Jocelyne","Zeng, Tiansheng","Francis, Magie","Xue, Bei","Roux, Melissa","Toloue Ostadgavahi, Ali","Rubino, Salvatore","Dawe, Nicholas J","Al-Ahdal, Mohammed N","Kelvin, David J","Richardson, Christopher D","Kindrachuk, Jason","Falzarano, Darryl","Kelvin, Alyson Anne"],"date":"2020-02-24T11:00:00Z","year":2020,"_id":"32088679","week":"20209|Feb 24 - Mar 01","doi":"10.3855/jidc.12425","keywords":["2019-nCoV","Wuhan","coronavirus","human-to-human transmission","vaccine readiness"],"source":"PubMed","locations":["Canada","Germany","Vietnam","United States","South Korea","Japan","Wuhan","China","France","Thailand"],"countries":["France","United States","Japan","Thailand","Canada","Korea, Republic of","Germany","China","Viet Nam"],"countries_codes":["FRA|France","USA|United States","JPN|Japan","THA|Thailand","CAN|Canada","KOR|Korea, Republic of","DEU|Germany","CHN|China","VNM|Viet Nam"],"topics":["Treatment"],"weight":1,"_version_":1661359647405113344,"score":182.15733}]}